





# Electronic Information Disclosure Statement

## TRPM-2 Antisense Therapy

Application:   
09/944326  
Confirmation: 2324  
Applicant(s): Martin Gleave  
Docket Number: UBC.P-020-2  
Group Art Unit: 1635  
Examiner: LaCourciere  
search string: (6383808).pn.

### US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
KAL	P01	6383808	2002-05-07		Monia	435	375

### Signature

Examiner Name	Date
<i>Kara LaCourciere</i>	11-17-03



Substitute for form 1449

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Application No. 09/944,326  
Applicant: Gleave et al  
Filing Date: August 10, 2001  
Title: TRPM-2 Antisense Therapy  
Attorney Docket No.: UBC.P-020-2

Page 1 of 2

**U.S. PATENT DOCUMENTS**

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

**FOREIGN PATENT DOCUMENTS**

	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	
KAL	Buttyn et al., "Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death" <i>Molecular and Cellular Biology</i> Aug. 1989, Vol. 9, No. 8, pp. 3473-3481
KAL	Millar et al., "Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous epithelium: fact or artefact?" <i>International Journal of Andrology</i> , 17:149-160
KAL	Darby et al., "Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity" <i>Exp Nephrol</i> 1995; 3:234-239
KAL	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays" <i>Nature Biotechnology</i> Volume 15, June 1997, pp. 537-541
KAL	Sensibar et al., "Prevention of Cell Death Induced by Tumor Necrosis Factor alpha in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin)," <i>Cancer Research</i> , June 1, 1995, Vol. 55, pp. 2431-2437
KAL	Miyake et al., "Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer", <i>Cancer Research</i> 60, January 1, 2000, pp. 170-176
KAL	Yang et al., "Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death", <i>Proc. Nat'l. Acad. Sci. USA</i> , Vol. 97, Issue 11, pp 5907-5912, May 23, 2000
KAL	Benner, et al., "Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies", <i>Journal of Pharmacological and Toxicological Method</i> , 37:229-235 (1997)



Substitute for form 1449

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Application No. 09/913,325

Applicant: Gleave et al

Filing Date: August 10, 2001

Title: TRPM-2 Antisense Therapy

Attorney Docket No.: UBC.P-020

Page 2 of 2

KAL	Kadomatsu, et al, "Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle", <i>Cancer Res</i> April 1, 1993, 53(7):1480-1483
KAL	Kyprianou, et al., "bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells.", <i>Int J Cancer</i> , Jan. 27, 1997, 70(3):341-348
KAL	Wright, et al., "A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts.", <i>Exp Cell Res</i> , Jan. 10, 1996, 222(1):54-60
KAL	Bruchovsky, et al., "Control of tumor progression by maintenance of apoptosis.", <i>Prostate Suppl.</i> , 1996, 6:13-21


This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Karen A. Proulx

Examiner Signature

11-17-03

Date Considered



INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Page 1 of 2

RECEIVED  
APR 01 2003  
TECH CENTER 1600/2900

Application No.: 09/944,326  
Applicant: Gleave, et al.  
Filing Date: 08/30/2001 # 9/K.T.  
Conf. No.: 2324 5/27  
Title: TRPM-2 Antisense Therapy  
Attorney Docket No.: I.D.S.  
UBC.P-020-2

U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
KAL	5,789,389	Tarasewicz et al.	08/04/1998
KAL	6,335,194 B1	Bennett et al.	01/01/2002

FOREIGN PATENT DOCUMENTS

Examiners Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
KAL	WO 01/46455 A2	Yale University	06/28/2001

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	
KAL	Nör et al.; Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth; Cancer Research; Vol. 61; March 1, 2001; 2183-2188.
KAL	Kirby et al.; Bartonella-Associated Endothelial Proliferation Depends on Inhibition of Apoptosis; PNAS; Vol. 99, No. 7; April 2, 2002; 4656-4661.
KAL	Cox et al.; Angiogenesis and Non-Small Cell Lung Cancer; Lung Cancer; Vol. 27, 2000; 81-100.
KAL	Tran et al.; A Role for Survivin in Chemoresistance of Endothelial Cells Mediated by VEGF; PNAS; Vol. 99, No. 7; April 2, 2002; 4349-4354.
KAL	Nör et al.; Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice; Laboratory Investigation; Vol. 81, No.4; April 2001; 453-463.
KAL	Boral et al.; Clinical Evaluation of Biologically Targeted Drugs: Obstacles and Opportunities; Cancer Chemother Pharmacol; Vol. 42; 1998; S3-S21.



INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Page 2 of 2

KAL	Zwain et al.; Clusterin Protects Granulosa Cells from Apoptotic Cell Death During Follicular Atresia; Experimental Cell Research; Vol. 257; 2000; 101-110.
KAL	Lee et al.; In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapoptotic Mediator; The Prostate Supplement; Vol. 9; 2000; 21-24.
KAL	Genta Incorporated; New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment; <a href="http://www.genta.com">www.genta.com</a> ; 2001.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

*Karen A. Pacourian*  
Examiner Signature

*11-17-03*  
Date Considered

RECEIVED

APR 01 2003

TECH CENTER 1600/2900

Application No.: 09/944,326  
Applicant: Gleave, et al.  
Filing Date: 08/30/2001  
Conf. No.: 2324  
Title: TRPM-2 Antisense Therapy  
Attorney Docket No.:  
UBC.P-020-2